10 results
10-K
2021 FY
IOBT
IO Biotech Inc
31 Mar 22
Annual report
5:07pm
inconsistent with the approved labeling, resulting in damage to our reputation and business.
We must comply with requirements concerning advertising … reputation in the marketplace among physicians and patients. There may also be increased risk of injury to patients if physicians attempt to use our products
10-Q
2021 Q3
IOBT
IO Biotech Inc
17 Dec 21
Quarterly report
4:55pm
in damage to our reputation and business.
We must comply with requirements concerning advertising and promotion for any product candidates for which … not effectively treat such conditions. Any such off-label use of our product candidates could harm our reputation in the
marketplace among physicians
424B4
IOBT
IO Biotech Inc
8 Nov 21
Prospectus supplement with pricing info
5:20pm
, reputation, revenue, financial results, and prospects, among other impacts:
our limited operating history and history of net losses since our inception … , or in a manner inconsistent with the approved labeling, resulting in damage to our reputation and business.
We must comply with requirements concerning
S-1
j478a
15 Oct 21
IPO registration
5:18pm
DRS/A
sgihbohv
6 Oct 21
Draft registration statement (amended)
12:00am
DRS/A
xdw0v9f
9 Aug 21
Draft registration statement (amended)
12:00am
DRS
r6sif83n
3 Jun 21
Draft registration statement
12:00am
- Prev
- 1
- Next